Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2018

View Archived Issues

Amyloid, Wnt, Dkk -- partners in crime

"Hot spots" in TP53 don't indicate oncogenic activity

Plug and play for chemistry, biology

P. acnes CAMP factor-associated inflammation in acne vulgaris: a potential vaccination strategy

SGM-101 is safe and effective for intraoperative imaging of pancreatic ductal adenocarcinoma

Optimized neuroimaging with fluorine-18-labeled SV2A PET tracers

Malaria transmission-blocking vaccine Pf25H-EPA/Alhydrogel does not prevent reinfection

Preclinical characterization and evaluation of the bacterial ribosome inhibitor NOSO-502

Positive data reported from phase Ib PK study of zilucoplan in patients with renal impairment

Dual oncoprotein inhibitors may treat pancreatic cancer

First patient dosed in phase II RESET CeD trial of Nexvax-2

Sunshine Lake Pharma patents influenza H1N1 inhibitors

Alnylam announces positive interim analysis results from ENVISION phase III study of givosiran

Progenra identifies new USP7 inhibitors for cancer

Positive final topline data presented from two phase II studies of imlifidase

Theravance Biopharma presents new JAK inhibitors

U.S. researchers divulge bacterial efflux pump inhibitors

Cidara Therapeutics initiates phase III ReSTOREstudy of rezafungin

MKP-5 inhibition may be therapeutic in pulmonary fibrosis

VPS-3 presents HDAC6 inhibitors

Ultragenyx reports topline cohort 2 data from phase I/II study of DTX-301 in OTC deficiency

Zealand initiates phase III trial of dasiglucagon for severe hypoglycemia in children

Tyme Technologies plans phase II trial of SM-88 in metastatic Ewing's sarcoma

Orphazyme reports topline phase II/III data on arimoclomol in Niemann-Pick disease Type C

FDA approves Emgality for preventive treatment of migraine in adults

Chitinase 3-like 1 protein as a novel therapeutic target in RSV-induced airway inflammation

FDA approves Vizimpro for first-line treatment of metastatic NSCLC with EGFR mutations

FLX Bio initiates phase I/II trial of FLX-475 in advanced cancers

FDA approves pediatric dose of Symjepi for emergency treatment of allergic reactions

Phase I results support advancement of oral carbapenem SPR-994 into pivotal phase III trial in cUTI

FFAR1 and FFAR4 as novel therapeutic targets in asthma

MJ8VAX vaccine demonstrates safety and immunogenicity in healthy adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...